Form 4: MBX Biosciences CFO Richard Bartram Acquires 95,000 Stock Options

Richard Bartram, CFO of MBX Biosciences, acquired 95,000 stock options with an exercise price of $10.49 on February 3, 2025.

Summary

• On February 3, 2025, Richard Bartram, the Chief Financial Officer of MBX Biosciences, acquired 95,000 stock options.
• The exercise price for these options is $10.49.
• 25% of the shares underlying the options will vest and become exercisable on February 3, 2026.
• The remaining 75% will vest in 36 equal monthly installments thereafter, contingent upon Bartram's continued service.
• The options expire on February 3, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and aligns management's interests with shareholders. There are no immediate negative implications.

Positives

• The acquisition of stock options by the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Future Outlook

The vesting schedule of the options incentivizes the CFO to remain with the company for at least three years to fully realize the value of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotech industry to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for stock option grants in similar-stage biotech companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CFO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates